Next-Gen NK Cell Platforms Show Promise In Cancer, Immune Recovery

In this segment of Cell & Gene Live, Building the Future of Cancer Immunotherapy Through Allogeneic NK Cell Innovation, expert panelists Raphael Ognar, President, CEO, and Co-Founder of NKILT Therapeutics and Tracy Ryan, Co-Founder and Chief Communications Officer of NKore BioTherapeutics, share why cutting-edge NK cell therapies are advancing through proprietary activation technologies that allow longer, more potent anti-cancer responses and unique immune system repair. NKILT’s platform uses receptor binding for broad target recognition. NCore’s platform combines osteoclasts and probiotic bacteria to supercharge NK cells and restore patient immunity. Clinical data show impressive persistence and tumor shrinkage with hopes for broader impact against both solid and liquid tumors.